Dieter Falkenburg
Vorstandsvorsitzender bei Novoplant GmbH
Profil
Dieter Falkenburg has been Chief Executive Officer of Novoplant GmbH since May 2004.
He joined ASTA Medica in 1990 as Manager of International Business Development.
He was appointed as Vice President of Business Development for MPB Cologne and Executive Vice President of Business Development for Direvo AG in 1999.
Dr. Falkenburg received a PhD from Ruprecht Karls University, Heidelberg.
Aktive Positionen von Dieter Falkenburg
| Unternehmen | Position | Beginn |
|---|---|---|
Novoplant GmbH
 Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Dieter Falkenburg
| Unternehmen | Position | Ende |
|---|---|---|
| ASTA Medica Oncology | Corporate Officer/Principal | - |
Ausbildung von Dieter Falkenburg
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Process Industries |
| ASTA Medica Oncology |
